title: Nilotinib risk evaluation and mitigation strategy.
authors.affiliation: University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Baer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003154:Community Medicine / Q000193:education; D006801:Humans; D007880:Legislation, Drug; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C498826:nilotinib